Recent News

• 03.04.2025 - AbbVie to Present at the Leerink Partners Global Healthcare Conference
• 03.03.2025 - AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
• 02.28.2025 - AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis
• 02.26.2025 - AbbVie to Present at the TD Cowen's 45th Annual Health Care Conference
• 02.14.2025 - AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors
• 02.13.2025 - AbbVie Declares Quarterly Dividend
• 02.12.2025 - Allergan Aesthetics To Launch Three New State-of-the-Art Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training
• 02.12.2025 - AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
• 02.07.2025 - U.S. FDA Approves EMBLAVEO™ (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections With Limited or No Treatment Options
• 02.07.2025 - U.S. FDA Approves EMBLAVEO™ (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections With Limited or No Treatment Options

Recent Filings